Go Pro
→ NNVC is Heading into a Major Clinical Catalyst! (From Equiscreen) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.02
+16.7%		$7.55
$5.37
▼
$17.58
$664.98M1.761.20 million shs2.54 million shs
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$20.36
+4.3%		$18.57
$8.31
▼
$21.39
$1.93B1.971.50 million shs520,713 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.63
+3.5%		$7.00
$2.55
▼
$9.42
$1.98B0.62.46 million shs1.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$182.10
+14.9%		$123.26
$23.30
▼
$180.94
$11.36B2.221.57 million shs2.39 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-8.77%+21.85%+26.51%-10.00%-30.53%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-4.45%-2.25%+6.61%+10.22%+108.32%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-1.21%+7.75%-12.57%+20.42%+168.98%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-3.71%+10.78%+12.57%+63.99%+473.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.02
+16.7%		$7.55
$5.37
▼
$17.58
$664.98M1.761.20 million shs2.54 million shs
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$20.36
+4.3%		$18.57
$8.31
▼
$21.39
$1.93B1.971.50 million shs520,713 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.63
+3.5%		$7.00
$2.55
▼
$9.42
$1.98B0.62.46 million shs1.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$182.10
+14.9%		$123.26
$23.30
▼
$180.94
$11.36B2.221.57 million shs2.39 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-8.77%+21.85%+26.51%-10.00%-30.53%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-4.45%-2.25%+6.61%+10.22%+108.32%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-1.21%+7.75%-12.57%+20.42%+168.98%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-3.71%+10.78%+12.57%+63.99%+473.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$6.33-36.77% Downside
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
2.36
Hold$22.008.06% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$6.83-10.38% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.50
Moderate Buy$103.00-43.44% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, FTRE, and MRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
BWS Financial logo
BWS Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$45.00
9/17/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$120.00 ➝ $160.00
9/9/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$2.50 ➝ $8.00
9/9/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
9/9/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral ➝ Hold$2.50 ➝ $8.00
9/9/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
BWS Financial logo
BWS Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$45.00
9/9/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$144.00
9/4/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$5.00
8/26/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$132.42M5.09N/AN/A$8.74 per share1.15
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$2.72B0.71$9.88 per share2.06$6.10 per share3.34
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$208.78M9.48$0.43 per share17.82$1.46 per share5.22
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$431.80M26.44N/AN/A$7.84 per share23.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$986.20M-$0.91N/A19.210.49-3.18%10.72%2.17%11/5/2026 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.52N/AN/AN/A-37.07%-15.70%-8.17%11/5/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$2.22N/AN/AN/A-31.66%-28.64%-19.94%11/13/2026 (Estimated)

Latest DNA, TWST, FTRE, and MRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.0435-$0.02+$0.0235-$0.08$48.67 million$51.44 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.5063-$0.56-$0.0538-$0.56$114.55 million$118.38 million
7/29/2026Q2 2026
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$0.1804$0.23+$0.0496-$0.14$647.57 million$678.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.98
0.96
0.96
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.49
4.05
2.98
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.67
2.38

Institutional Ownership

CompanyInstitutional Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.73%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.49%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
48567.34 million58.80 millionOptionable
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
14,30095.10 million94.41 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
415259.67 million253.21 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
97962.71 million60.78 millionOptionable

Recent News About These Companies

Twist Bioscience (NASDAQ:TWST) Trading 8.9% Higher - Here's Why
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-twist-bioscience-nasdaq-twst-trading-89-higher-heres-why-2026-09-24/
Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 348 Shares of Stock
September 24 at 6:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044841
Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 294 Shares of Stock
September 24 at 6:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-twst-insider-buying-and-selling-2026-09-24/
Corient Private Wealth LP Takes $2.23 Million Position in Twist Bioscience Corporation $TWST
September 24 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-takes-223-million-position-in-twist-bioscience-corporation-twst-2026-09-24/
Paula Green Sells 294 Shares of Twist Bioscience (NASDAQ:TWST) Stock
September 23 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-paula-green-sells-294-shares-of-twist-bioscience-nasdaq-twst-stock-2026-09-23/
Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $57,590.52 in Stock
September 23 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-twist-bioscience-nasdaq-twst-insider-sells-5759052-in-stock-2026-09-23/
Emily Leproust Sells 1,687 Shares of Twist Bioscience (NASDAQ:TWST) Stock
September 23 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-emily-leproust-sells-1687-shares-of-twist-bioscience-nasdaq-twst-stock-2026-09-23/
Twist Bioscience Slides as Recent Rally Cools and CEO Sale Filing Weighs on Sentiment
September 23 at 1:50 PM  |  quiverquant.comQ
Twist Bioscience (NASDAQ:TWST) Hits New 12-Month High - Here's Why
September 23 at 4:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042002
Twist Bioscience (NASDAQ:TWST) Sets New 1-Year High - Should You Buy?
September 23 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-twist-bioscience-nasdaq-twst-sets-new-1-year-high-should-you-buy-2026-09-23/
3 Analysts, 3 Trades to Make Today
September 22 at 5:00 PM  |  investorplace.comhttps://investorplace.com/2026/09/3-analysts-3-trades-to-make-today/
Twist Bioscience (TWST) Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
September 22 at 7:10 AM  |  insidermonkey.comhttps://www.insidermonkey.com/news/twist-bioscience-twst-expands-ai-drug-discovery-exposure-with-lilly-tunelab-partnership-1840752/
Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 356,546 Shares of Stock
September 22 at 4:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-twst-insider-buying-and-selling-2026-09-22/
Practice caution with this hot stock up 493% in the past year
September 21 at 8:00 PM  |  msn.comhttps://www.msn.com/en-us/general/general/practice-caution-with-this-hot-stock-up-493-in-the-past-year/ar-AA2cHnSA
Emily Leproust Sells 356,546 Shares of Twist Bioscience (NASDAQ:TWST) Stock
September 21 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-emily-leproust-sells-356546-shares-of-twist-bioscience-nasdaq-twst-stock-2026-09-21/
BWS Financial Reiterates Sell Rating for Twist Bioscience (NASDAQ:TWST)
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033726
922,647 Shares in Twist Bioscience Corporation $TWST Purchased by Bank of America Corp DE
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-922647-shares-in-twist-bioscience-corporation-twst-purchased-by-bank-of-america-corp-de-2026-09-19/
Why Twist Bioscience Stock Skyrocketed This Week
September 18, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/18/why-twist-bioscience-stock-skyrocketed-this-week/
【TWST】Twist Bioscience W
September 18, 2026  |  note.comN
Twist Bioscience (NASDAQ:TWST) Earns Sell Rating from BWS Financial
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-twist-bioscience-nasdaq-twst-earns-sell-rating-from-bws-financial-2026-09-18/
TWST Stock Hits Multi-Year High, But ‘Pharma Bro’ Martin Shkreli Calls Twist A Short
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/twst-stock-hits-multi-high-214446723.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$10.02 +1.44 (+16.74%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Fortrea stock logo

Fortrea NASDAQ:FTRE

$20.36 +0.84 (+4.30%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$7.62 +0.26 (+3.46%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$182.10 +23.60 (+14.89%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas